AVRO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide...

Stats
Today's Volume	39 131.00
Average Volume	291 012
Market Cap	53.83M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.360 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	4.44
ATR14	$0.00500 (0.41%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-01	Golipour Azadeh	Sell	37 334	Restricted Stock Unit
2024-02-01	Golipour Azadeh	Buy	37 334	Common Stock
2024-02-05	Golipour Azadeh	Sell	12 232	Common Stock
2024-02-01	Ridha Essra	Sell	32 834	Restricted Stock Unit
2024-02-01	Ridha Essra	Buy	32 834	Common Stock

INSIDER POWER
54.81
Last 100 transactions
Buy: 6 327 240 \| Sell: 1 294 974

Volume Correlation

Long: 0.15 (neutral)

Short: 0.93 (very strong)

Signal:(56.529) Expect same movement, but be aware

AVROBIO Inc Correlation

10 Most Positive Correlations
TLS	0.933
MBIN	0.909
HUBG	0.893
ALLK	0.892
PMBC	0.888
NBTB	0.884
ITOS	0.876
ATNX	0.873
CLOV	0.873
LTRX	0.871

10 Most Negative Correlations
AAON	-0.865
DPCS	-0.861
GRPH	-0.851
BNIXU	-0.845
CINC	-0.844
SGEN	-0.842
IPAR	-0.841
XLNX	-0.829
RETA	-0.826
VCXA	-0.823

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AVROBIO Inc Correlation - Currency/Commodity

-0.26
( neutral )

-0.20
( neutral )

0.00
( neutral )

0.08
( neutral )

AVROBIO Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-617 000 (0.00 %)
EPS:	$0.270

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.200

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.480

Q2	2023
Revenue:	$0
Gross Profit:	$-879 000 (0.00 %)
EPS:	$1.530

Financial Reports:

No articles found.

AVROBIO Inc

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.